Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared a post on X:
“ctDNA profiling in GEA: can liquid biopsies anticipate relapse before imaging?
- cfDNA profiling was feasible across localized and M1 GEA.
- On-treatment ctDNA clearance associated with improved survival.
- ctDNA resurgence/persistence predicted recurrence a median of 7 months before imaging.
The first sign of progression is already floating in the bloodstream!”
Title: Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
Authors: Samuel L. Cytryn, Raktim Borpatragohain, Karmelina Charalambous, William Phu, Ronak Shah, Samuel Nussenzweig, Steven B. Maron, Henry Walch, Walid K. Chatila, Efsevia Vakiani, Angela R. Brannon, Marc Ladanyi, Fiona Socolow, Smita Joshi, Ping Gu, Ryan Sugarman, Geoffrey Y. Ku, David H. Ilson, Katherine D. Gray, David R. Jones, Bernard J. Park, Matthew J. Bott, James M. Isbell, David B. Solit, Michael F. Berger, Vivian Strong, Daniela Molena, Yelena Y. Janjigian, Smita Sihag
Other articles featuring Mario Balsa on OncoDaily.